Edition:
United Kingdom

People: Allogene Therapeutics Inc (ALLO.OQ)

ALLO.OQ on NASDAQ Stock Exchange Global Select Market

29.03USD
22 May 2019
Change (% chg)

$-0.09 (-0.31%)
Prev Close
$29.12
Open
$29.10
Day's High
$29.62
Day's Low
$28.59
Volume
103,596
Avg. Vol
119,360
52-wk High
$35.55
52-wk Low
$21.67

Moore, Alison 

Dr. Alison Moore, Ph.D., serves as Chief Technical Officer of the Company, She has served as our Chief Technical Officer since June 2018. Prior to joining us, she most recently served as Senior Vice President, Process Development at Amgen Inc. from January 2013 until June 2018. Dr. Moore has previously held senior roles at Amgen in Operations Technology from January 2013 until August 2014, Process and Product engineering from January 2011 until January 2013, and Corporate Manufacturing from August 2008 until December 2010. Prior to these positions, she was Vice President, Site Operations at Amgen’s Fremont, California, manufacturing facility, from March 2006 until August of 2008. Before joining Amgen, from 2005 to 2006, Dr. Moore was a Director in Chemistry, Manufacturing and Controls, and Regulatory Affairs at Genentech, Inc. Prior to Genentech, she was a Postdoctoral Research Fellow at the Medical University of Lübeck, Germany. Dr. Moore holds both a bachelor’s degree in Pharmacology with Honors and a Ph.D. in Cell Biology from Manchester University, England.

Basic Compensation

Total Annual Compensation, USD 233,265
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,603,350
Fiscal Year Total, USD 1,836,610

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Arie Belldegrun

10,046,200

David Chang

12,848,500

Joshua Kazam

3,592,470

Eric Schmidt

2,588,990

Alison Moore

1,836,610

David Bonderman

--
As Of  31 Dec 2018